Home Category Region Publishers About Us Contact Us
Home > Market Research Report > Pharmaceutical > Mental Disease > How Will Deep Brain Stimulation Affect Neurological and Psychiatric Drug Markets?
Category
Pharmaceutical (4988)
Bone Disease Treatment (46)
Cancer (883)
Diabetes (159)
Drug Delivery System (184)
Drug Discovery (1403)
Generic Drugs (128)
Infectious Disease (406)
Mental Disease (98)
Neurodegenerative Disease (180)
Obesity Treatment (49)
OTC Drug (149)
Pharmaceutical Companies (561)
Prescription Drugs (120)
Regulation (122)
Vaccines (178)
Veterinary Medicine (28)
Market Research Report

How Will Deep Brain Stimulation Affect Neurological and Psychiatric Drug Markets?

Published by Decision Resources, Inc.
Published August, 2006 Product code 44414
Content info 26 Pages
Price
Not Available

This publication has been discontinued on December 21, 2011.

Introduction

Abstract

Introduction

Deep brain stimulation (DBS) is currently approved only to treat Parkinson's disease and Parkinson-like symptoms; however, clinical trials are under way for DBS in several other neurological and psychiatric disorders. As these surgical interventions gain acceptance in the face of conventional therapies' shortcomings in severely affected patients, opportunities are emerging for such devices, used both alone and in conjunction with existing drug regimens.

Get the Answers You Need to Shape Your Strategy

Currently, DBS is approved only for parkinsonism. For what other indications is DBS being investigated? What advantages does DBS offer to treat these indications? What potential exists for DBS in these indications? The risk factors associated with DBS have made it a last-resort therapy for most indications. How competitive will DBS be with conventional drug therapies? In which indications will it stand out? Will DBS ever be used as an early therapy, in any indication? Medtronic is the only company to have an approved device for DBS, although several companies have devices in development for other indications. Which of the companies developing DBS devices is best positioned to succeed in these new markets? What innovations must these companies provide to ensure success? Which company is poised to collaborate with drugmakers in creating a viable combination therapy?

Table of Contents

  • Executive Summary
  • Strategic Implications
  • Stakeholder Implications
  • Introduction
  • Overview of DBS
  • DBS for Specific Therapeutic Areas
  • Parkinson's Disease
  • Epilepsy
  • Psychiatric Disorders: OCD and Depression
  • Headaches
  • Companies Developing DBS Systems
  • Medtronic
  • NeuroPace
  • Cyberonics
  • Boston Scientific
  • Medtrode
  • Advanced Neuromodulation Systems
  • Impact of DBS on Drug Markets
  • Market Implications
  • DBS and the PD Market
  • DBS and the Epilepsy Market
  • DBS and the Psychiatric Markets
  • DBS and the Headache Market
  • Codevelopment of Pharmacological Agents and DBS
  • Outlook for DBS in the Marketplace
  • Bibliography

Tables

  • 1. Brain Regions Implicated in Epileptic Seizures
  • 2. Companies Developing DBS Devices

Figures

  • 1. Regions of the Brain Targeted for Deep Brain Stimulation
  • 2. Schematic of Deep Brain Stimulation
  • 3. Growth of DBS Procedures, by Indication, 2005-2015
Back to Top